Xeris制药（股票代码：XERS）今日盘中大涨6.36%，引发市场关注。该公司刚刚公布了2025年第一季度财报，营收表现亮眼。
根据财报显示，Xeris制药第一季度营收达到6012万美元，同比增长47.9%，超过分析师预期的5761万美元。尽管调整后每股亏损6美分，略高于分析师预期的5美分，但仍较去年同期的14美分亏损有明显改善。公司本季度净亏损为922万美元。
值得注意的是，尽管本季度业绩略低于预期，但华尔街分析师对Xeris制药保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中5个"强烈买入"或"买入"评级，1个"持有"评级，没有"卖出"或"强烈卖出"评级。分析师给出的12个月目标价中位数为6.25美元。此外，过去三个月里，分析师的平均盈利预期上升了约20%，显示出对公司未来发展的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.